- In June 2024, Medtronic plc, a global healthcare technology leader, announced the launch of its innovative Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to simplify the implant process and improve lifetime patient management, making it an ideal choice for cardiac surgeons and patients seeking a future-ready aortic valve solution
- In September 2024, Edwards Lifesciences launched the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with the Alterra adaptive prestent in Europe. This expansion of minimally invasive treatment options offers a broader range of patients with congenital heart conditions access to advanced care
- In May 2023, Edwards Lifesciences introduced the Sapien 3 Ultra Resilia valve in Europe. This transcatheter aortic valve replacement (TAVR) system is the first to incorporate the company's Resilia tissue technology, which is designed to improve valve durability
- In December 2022, Abbott announced the launch of its latest Navitor transcatheter aortic valve implantation (TAVI) system in India. This minimally invasive device is now available for patients with severe aortic stenosis who are at high or extreme surgical risk
- In September 2020, Boston Scientific Corporation initiated a controlled launch of the ACURATE neo2 Aortic Valve System in Europe. This advanced transcatheter aortic valve implantation (TAVI) system offers improved clinical performance over its predecessor and has expanded indications for patients with aortic stenosis, regardless of age or risk level, provided they are suitable candidates for therapy
